Cargando…

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation

The therapeutic landscape of chronic myeloid leukemia (CML) has changed dramatically in the last decade. In particular, the availability of imatinib mesylate, a tyrosine kinase inhibitor targeting BCR-ABL, has led to profound and durable remissions in the majority of patients. However, a couple of i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piccaluga, Pier Paolo, Paolini, Stefania, Bertuzzi, Clara, De Leo, Antonio, Rosti, Gianantonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514971/ https://www.ncbi.nlm.nih.gov/pubmed/23226701 http://dx.doi.org/10.2147/JBM.S13067

Ejemplares similares

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
por: Breccia, Massimo, et al.
Publicado: (2017)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
por: Hochhaus, Andreas, et al.
Publicado: (2017)

Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib
por: Angelopoulou, M K, et al.
Publicado: (2016)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
por: Giles, Francis J., et al.
Publicado: (2017)

Treatment Recommendations for Chronic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia
por: Kim, Da Jung, et al.
Publicado: (2019)

Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript
por: Greco, Marianna, et al.
Publicado: (2013)

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
por: Drube, Julia, et al.
Publicado: (2018)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
por: Patel, Vihang, et al.
Publicado: (2017)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
por: Maruta, Shunsuke, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?
por: Capuozzo, Maurizio, et al.
Publicado: (2014)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia
por: Ismail, Abdel-Latif S, et al.
Publicado: (2020)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
por: Al-Dubai, Husam N., et al.
Publicado: (2020)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
por: Hochhaus, A, et al.
Publicado: (2016)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report
por: Caocci, Giovanni, et al.
Publicado: (2014)

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
por: Sanford, David, et al.
Publicado: (2014)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
por: Cengiz Seval, Güldane, et al.
Publicado: (2017)

OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia
por: Kiriyama, Hiroyuki, et al.
Publicado: (2019)

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
por: Galimberti, Sara, et al.
Publicado: (2017)

Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report
por: Centrone, Renato, et al.
Publicado: (2020)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
por: Steegmann, Juan Luis, et al.
Publicado: (2017)

Dysplastic Nevus with Eruptive Melanocytic Lesions That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia
por: Lee, Joo Hyun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bg1tqti23kags1ujprdlk9bjpf